Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph W Basler

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Southern Medical Journal|September 3, 2011
Socioeconomic disparities in prostate cancer mortalityJoseph W Basler
Current Urology Reports|June 15, 2006
Efficacy of taxotere in the post-prostatectomy settingJoseph W Basler
The Journal of Urology|January 10, 2004
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemopreventionJoseph W Basler, Gary A Piazza
Journal of Cancer|January 4, 2011
Prognostic factors for failure after prostatectomyGregory P Swanson, Joseph W Basler
Current Urology Reports|May 5, 2005
Multidisciplinary management of prostate malignancyJoseph W Basler, Carol Jenkins, Gregory Swanson
The Urologic Clinics of North America|May 5, 2004
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditionsJavier Hernandez, Joseph W Basler, Ian M Thompson
Current Urology Reports|April 25, 2006
Dealing with non-cancerous findings on prostate biopsyTimothy C Brand, Gregory P Thibault, Joseph W Basler
International Journal of Surgical Pathology|May 7, 2010
Intraductal carcinoma of the prostate in the ejaculatory ductAlma J Sanchez-Salazar, Joseph W Basler, Marlo M Nicolas
Current Oncology Reports|April 7, 2004
What's new in the field of prostate cancer chemoprevention?Kanwaljit Mahal, Javier Hernandez, Joseph W Basler, et al.
Current Urology Reports|May 5, 2005
What's new in the field of prostate cancer chemoprevention?Kanwaljit Mahal, Javier Hernandez, Joseph W Basler, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Southern Medical Journal|September 3, 2011
Socioeconomic disparities in prostate cancer mortalityJoseph W Basler
Current Urology Reports|June 15, 2006
Efficacy of taxotere in the post-prostatectomy settingJoseph W Basler
The Journal of Urology|January 10, 2004
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemopreventionJoseph W Basler, Gary A Piazza
Journal of Cancer|January 4, 2011
Prognostic factors for failure after prostatectomyGregory P Swanson, Joseph W Basler
Current Urology Reports|May 5, 2005
Multidisciplinary management of prostate malignancyJoseph W Basler, Carol Jenkins, Gregory Swanson
The Urologic Clinics of North America|May 5, 2004
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditionsJavier Hernandez, Joseph W Basler, Ian M Thompson
Current Urology Reports|April 25, 2006
Dealing with non-cancerous findings on prostate biopsyTimothy C Brand, Gregory P Thibault, Joseph W Basler
International Journal of Surgical Pathology|May 7, 2010
Intraductal carcinoma of the prostate in the ejaculatory ductAlma J Sanchez-Salazar, Joseph W Basler, Marlo M Nicolas
Current Oncology Reports|April 7, 2004
What's new in the field of prostate cancer chemoprevention?Kanwaljit Mahal, Javier Hernandez, Joseph W Basler, et al.
Current Urology Reports|May 5, 2005
What's new in the field of prostate cancer chemoprevention?Kanwaljit Mahal, Javier Hernandez, Joseph W Basler, et al.
Pageof 3